|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Received Date ICMJE | July 21, 2005 | ||||
| Last Updated Date | August 1, 2005 | ||||
| Start Date ICMJE | October 1997 | ||||
| Primary Completion Date | |||||
| Current Primary Outcome Measures ICMJE |
To test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years | ||||
| Original Primary Outcome Measures ICMJE |
To test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years. | ||||
| Change History | Complete list of historical versions of study NCT00123669 on ClinicalTrials.gov Archive Site | ||||
| Current Secondary Outcome Measures ICMJE | |||||
| Original Secondary Outcome Measures ICMJE | |||||
| Descriptive Information | |||||
| Brief Title ICMJE | Primary Progesterone Therapy for Operable Breast Cancer | ||||
| Official Title ICMJE | The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial | ||||
| Brief Summary | The purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer. The study addresses two issues related to breast cancer surgery:
|
||||
| Detailed Description | This protocol addresses the issue of pre-operative hormone manipulation in women with operable breast cancer. The study has been designed after careful review of literature to assess the effect of unopposed oestrogen at the time of surgery and collect evidence that events at the time of surgery may have impact on the long-term survival of breast cancer patients. The meta-analysis of 37 studies on timing of surgery during the menstrual cycle showed a 15% + 3 improvement in survival for women who had undergone surgery during the luteal phase of their menstrual cycle. Three of the 37 studies where progesterone levels were estimated at the time of surgery showed 52% + 26 improvement in survival when circulating progesterone were > 1.5 ng/ml. The study aims to produce luteal milieu by injecting Hydroxy- progesterone 500 mg IM at the time of surgery. The timing of administration of progesterone in the neo-adjuvant setting is decided after collating data from large data-bases and randomised trials of screening suggesting that events at the time of surgery may alter the behavior of micro-metastases. |
||||
| Study Phase | Phase III | ||||
| Study Type ICMJE | Interventional | ||||
| Study Design ICMJE | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study | ||||
| Condition ICMJE | Breast Neoplasms | ||||
| Intervention ICMJE | Drug: Depot preparation of Hydroxyprogesterone hexanoate 500mg | ||||
| Study Arms / Comparison Groups | |||||
| Publications * |
|
||||
|
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||
| Recruitment Information | |||||
| Recruitment Status ICMJE | Active, not recruiting | ||||
| Enrollment ICMJE | 1000 | ||||
| Completion Date | |||||
| Primary Completion Date | |||||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
| Gender | Female | ||||
| Ages | 18 Years to 75 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
| Location Countries ICMJE | India | ||||
| Administrative Information | |||||
| NCT ID ICMJE | NCT00123669 | ||||
| Responsible Party | |||||
| Study ID Numbers ICMJE | No. SP/SO/B29/2000 | ||||
| Study Sponsor ICMJE | Tata Memorial Hospital | ||||
| Collaborators ICMJE | Ministry of Science and Technology, India | ||||
| Investigators ICMJE |
|
||||
| Information Provided By | Tata Memorial Hospital | ||||
| Verification Date | April 2005 | ||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||